Physician profile

Eric H Espensen

Foot & Ankle Surgery · Tucson, AZ

NPI 1497786750

$1,200.60

in general payments reported to CMS, 2019-2025

6 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$547.91
Consulting Fee$280.25

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Stryker Corporation $728.26 2022-2024 Anchorage, Augment Injectable
Becton, Dickinson and Company $280.25 2024
Smith+Nephew, INC. $132.73 2019
Integra Lifesciences Corporation $33.19 2019
Electronic Waveform Lab, INC. $13.78 2022
Advanced Oxygen Therapy INC. $12.39 2024 Topical Oxygen Chamber For Extremities

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Eric H Espensen

$1,200.60

in general payments reported 2019-2025

Years
2019-2024
Top company
Stryker Corporation

https://glasscript.com/doctor/294217/eric-h-espensen

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.